Myotonic dystrophies 1 and 2: complex diseases with complex mechanisms. - sprookjes - yvandenbroek - TriplyDB

Myotonic dystrophies 1 and 2: complex diseases with complex mechanisms.

Myotonic dystrophies 1 and 2: complex diseases with complex mechanisms.

http://www.wikidata.org/entity/Q33867667

about

Feedback Regulation of Kinase Signaling Pathways by AREs and GREs A muscle stem cell for every muscle: variability of satellite cell biology among different muscle groups The importance of CELF control: molecular and biological roles of the CUG-BP, Elav-like family of RNA-binding proteins RNA-binding proteins and gene regulation in myogenesis The RNA-binding protein Staufen1 is increased in DM1 skeletal muscle and promotes alternative pre-mRNA splicing New function for the RNA helicase p68/DDX5 as a modifier of MBNL1 activity on expanded CUG repeats Muscleblind-like 1 is required for normal heart valve development in vivo.Expanded CCUG repeat RNA expression in Drosophila heart and muscle trigger Myotonic Dystrophy type 1-like phenotypes and activate autophagocytosis genes.Recent progress in histochemistry and cell biology.MBNL proteins and their target RNAs, interaction and splicing regulation.C9ORF72 repeat expansion in Australian and Spanish frontotemporal dementia patients Antisense therapy in neurology Smaug/SAMD4A restores translational activity of CUGBP1 and suppresses CUG-induced myopathy.Small molecules that target the toxic RNA in myotonic dystrophy type 2.Overexpression of CUGBP1 in skeletal muscle from adult classic myotonic dystrophy type 1 but not from myotonic dystrophy type 2.RNA Foci, CUGBP1, and ZNF9 are the primary targets of the mutant CUG and CCUG repeats expanded in myotonic dystrophies type 1 and type 2 Identification of Targets of CUG-BP, Elav-Like Family Member 1 (CELF1) Regulation in Embryonic Heart Muscle.CUG-BP1 regulates RyR1 ASI alternative splicing in skeletal muscle atrophy.CELFish ways to modulate mRNA decay.CUG-BP, Elav-like family (CELF)-mediated alternative splicing regulation in the brain during health and disease.Identification and characterization of DM1 patients by a new diagnostic certified assay: neuromuscular and cardiac assessments.Staufen1 impairs stress granule formation in skeletal muscle cells from myotonic dystrophy type 1 patients.Molecular mechanisms of muscle atrophy in myotonic dystrophies.RNA binding proteins in the regulation of heart development.GSK3β is a new therapeutic target for myotonic dystrophy type 1.Nucleolar aggresomes as counterparts of cytoplasmic aggresomes in proteotoxic stress. Proteasome inhibitors induce nuclear ribonucleoprotein inclusions that accumulate several key factors of neurodegenerative diseases and cancer.Positive muscle phenomena--diagnosis, pathogenesis and associated disorders.The role of CUGBP1 in age-dependent changes of liver functions.Brain pathology in myotonic dystrophy: when tauopathy meets spliceopathy and RNAopathy.Clinical aspects, molecular pathomechanisms and management of myotonic dystrophies.Activation of the innate immune response and interferon signalling in myotonic dystrophy type 1 and type 2 cataracts.Identification of exosomal muscle-specific miRNAs in serum of myotonic dystrophy patients relating to muscle disease progress.(CCUG)n RNA toxicity in a Drosophila model of myotonic dystrophy type 2 (DM2) activates apoptosis.Cultured myoblasts from patients affected by myotonic dystrophy type 2 exhibit senescence-related features: ultrastructural evidence.RNA-binding proteins regulate the expression of the immune activating ligand MICB.Nuclear ribonucleoprotein-containing foci increase in size in non-dividing cells from patients with myotonic dystrophy type 2.Correction of GSK3β at young age prevents muscle pathology in mice with myotonic dystrophy type 1.Alternative splicing alterations of Ca2+ handling genes are associated with Ca2+ signal dysregulation in myotonic dystrophy type 1 (DM1) and type 2 (DM2) myotubes.Misregulation of calcium-handling proteins promotes hyperactivation of calcineurin-NFAT signaling in skeletal muscle of DM1 mice.RNA processing is altered in skeletal muscle nuclei of patients affected by myotonic dystrophy

P2860

Q26773059-FE9BE831-C9E7-4429-A786-75E44D1AD96C Q26779289-A789EFA4-5DB5-47FD-A53E-A3D9A0E9D0C5 Q26823119-D1BACF07-3034-4C27-B411-AC085CFF67FC Q26866134-4A06CCF0-030D-48E8-9F33-838E73CCACA1 Q30424920-E7EEA1D6-7599-421B-85AD-DEA3B89E5830 Q30427374-F83B6201-A427-4311-B63C-426F2ED28B31 Q30668792-CE51CA6E-90DE-4EAD-B0C6-65AF3CCD40A3 Q30854929-7AB8E5EF-F156-4174-B60A-3AD450C5FD9B Q34172616-97EF4C8C-28F7-47D9-B28A-AEE3F627215D Q34248811-00D5CFEA-0A60-44A3-BDB8-5B907A614607 Q34599648-CE15061B-604F-4F07-A848-D5CB8039F269 Q34608717-C73645E2-590A-4FE2-988A-3C33247DF7FE Q34699771-059D54BF-EF58-4AD6-94BB-425B109018FC Q35061734-E3259F27-2C64-452D-9E1E-84B7E90E29D7 Q35078193-A06993FD-0EA1-4462-85D4-0C3037B8ED3D Q35474587-EF141105-6BB1-4ADC-918C-B14374AF1938 Q35920624-DABD1563-7DCA-49AF-B224-5B4F41FEA51D Q36245773-3E6218FE-0225-4311-8559-E23C2CAAFF3B Q36807677-F192B600-FA8F-40F2-8287-8BBA710AF3AD Q36831893-6F8F0C8B-4640-4BDA-829E-CD045B3F8623 Q36879671-676AB0D1-A878-4946-9092-1D9DC9A64AF5 Q36944554-3F145593-D118-4FDD-9600-CC794EF8F8EF Q37138514-F86C2A24-224F-4C39-8C35-04D16D2AA825 Q37245183-BC358905-ADC7-4F6E-8369-43467964690F Q37590296-6D1ABC31-D6C7-4F34-9278-FB69386F991A Q37855730-A7730EBA-A136-47D4-885D-8754F727161D Q37978120-B9C336D7-C4CE-49E6-BEA6-7F754684A721 Q37996811-824BA84E-01BE-4F14-8F7D-551FABF79496 Q38177257-C736253E-9C02-4978-8C8D-5D22DC7EC9F3 Q38209927-9F582B88-F222-4875-9942-893FE9C1448C Q38330480-C0F6DF3C-D684-43B4-AADC-03DA85F83CBE Q38432204-212EB1E3-FB67-4BDE-B171-9E9684E92FBC Q38721747-4CD5BEC1-5AED-4126-97C6-97C39F70F0CB Q38852912-83C9A28F-06EE-49C1-BFCC-43629791FE51 Q40919209-6A7A55BF-98B6-4F25-A16B-334DD76A39DE Q47303392-EA3708D5-FEA6-42F8-9DA5-1ED46A992DFA Q47332454-E568B65C-C1C1-4870-BB87-3C79E75365C8 Q47929916-370CB598-38A6-49A2-A78D-F94E0144A564 Q50755664-5CA51F1B-BE10-482F-9F7A-C46F6EB3FCD5 Q57085790-9BE145F7-CB8F-4D01-8E3F-88255A304085

P2860

Myotonic dystrophies 1 and 2: complex diseases with complex mechanisms.

http://www.wikidata.org/entity/Q33867667

description

2010 nî lūn-bûn

@nan

2010 թուականի Ապրիլին հրատարակուած գիտական յօդուած

@hyw

2010 թվականի ապրիլին հրատարակված գիտական հոդված

@hy

2010年の論文

@ja

2010年論文

@yue

2010年論文

@zh-hant

2010年論文

@zh-hk

2010年論文

@zh-mo

2010年論文

@zh-tw

2010年论文

@wuu

name

Myotonic dystrophies 1 and 2: complex diseases with complex mechanisms.

@ast

Myotonic dystrophies 1 and 2: complex diseases with complex mechanisms.

@en

type

label

Myotonic dystrophies 1 and 2: complex diseases with complex mechanisms.

@ast

Myotonic dystrophies 1 and 2: complex diseases with complex mechanisms.

@en

prefLabel

Myotonic dystrophies 1 and 2: complex diseases with complex mechanisms.

@ast

Myotonic dystrophies 1 and 2: complex diseases with complex mechanisms.

@en

P1433

Q33867667-2A487F16-3238-4FFB-BF4E-E5303D1E0009

P1476

Q33867667-7A0BB64A-04B8-4D13-8A6B-68465387C486

P2093

Q33867667-DCF5D1D2-8964-4611-90BA-AD63F0C0AE6A

P2860

Q33867667-02E2150B-E5DC-4910-B773-09112CDEE412

Q33867667-08D3DFBE-0FF9-44F1-A59E-6A952D38EF2C

Q33867667-0C61B430-447F-4021-BB64-57986852BD01

Q33867667-0CC71B74-F376-485B-94D0-25A58F689349

Q33867667-0E897788-A192-48B3-B533-68D06EA8E217

Q33867667-1094ED85-24D4-48FE-99EF-02BFEF4930E2

Q33867667-14CF0CF1-B7D2-4594-B477-4E44DA364F96

Q33867667-1B54AF6C-7981-41CF-836A-2B3614E789F2

Q33867667-1CCE8E54-A261-460C-BC8D-9D1799524607

Q33867667-1F562E93-B6E9-4F79-91FF-1649D9A64239

P304

Q33867667-8A757107-F7D0-4961-829E-3E575231CD84

P31

Q33867667-AB7173B5-8294-4575-AE06-87C8400D115B

P356

Q33867667-7CFA3566-62A6-44A8-A733-2BA0F77E62B4

P433

Q33867667-C0860417-E99B-4ED6-AC02-A2991AA6AD64

P478

Q33867667-E2F36C92-35F5-428C-ADF6-0CDEB0DAD9A4

P50

Q33867667-47671047-F5C9-4D23-BAD5-8036D4E4829C

P577

Q33867667-78257C87-D433-45AF-B8BD-6D40F8FB702A

P5875

Q33867667-3B4BD0C5-989B-43E8-BCFC-512AB4B3956F

P698

Q33867667-330C4600-8831-452F-AEE7-8C2F0280FAB3

P932

Q33867667-C94808E1-ACC7-45A2-A739-B5483FD07824

P356

138920210790886844

P1433

Current Genomics

P1476

Myotonic dystrophies 1 and 2: complex diseases with complex mechanisms

@en

P2093

Lubov Timchenko

http://www.w3.org/2001/XMLSchema#string

P2860

Recruitment of human muscleblind proteins to (CUG)(n) expansions associated with myotonic dystrophy

Competition of CUGBP1 and calreticulin for the regulation of p21 translation determines cell fate.

Identification of a (CUG)n triplet repeat RNA-binding protein and its expression in myotonic dystrophy

Failure of MBNL1-dependent post-natal splicing transitions in myotonic dystrophy

EDEN and EDEN-BP, a cis element and an associated factor that mediate sequence-specific mRNA deadenylation in Xenopus embryos.

CUG-BP binds to RNA substrates and recruits PARN deadenylase

Molecular basis for impaired muscle differentiation in myotonic dystrophy

Visualization of double-stranded RNAs from the myotonic dystrophy protein kinase gene and interactions with CUG-binding protein

CUG repeat binding protein (CUGBP1) interacts with the 5' region of C/EBPbeta mRNA and regulates translation of C/EBPbeta isoforms

Conserved GU-rich elements mediate mRNA decay by binding to CUG-binding protein 1

P304

77-90

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.2174/138920210790886844

http://www.w3.org/2001/XMLSchema#string

P433

2

http://www.w3.org/2001/XMLSchema#string

P478

11

http://www.w3.org/2001/XMLSchema#string

P50

Benedikt Schoser

P577

2010-04-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

47157450

http://www.w3.org/2001/XMLSchema#string

P698

20885816

http://www.w3.org/2001/XMLSchema#string

P932

2874224

http://www.w3.org/2001/XMLSchema#string